ライフサイエンスコーパス: weight loss

1 ion, portal hypertension, malabsorption, and weight loss).

2 ponded inconsistently to FGF21 treatment and weight loss.

3 ring may decrease weight regain and improve weight loss.

4 reased, and this was associated with greater weight loss.

5 s fiber may have the potential to facilitate weight loss.

6 ar surgical intervention to induce sustained weight loss.

7 tive potential of baseline blood proteins on weight loss.

8 ory tract, causing slight fever and moderate weight loss.

9 es and exercise, with the primary goal being weight loss.

10 body mass index (BMI), duration of T2DM, and weight loss.

11 (>=40 kg/m2), for which risk was lowest with weight loss.

12 st-treatment and was associated with greater weight loss.

13 ge upon dietary intervention and concomitant weight loss.

14 ge, though they experienced viremia and body weight loss.

15 ve insulin sensitivity despite marked (~20%) weight loss.

16 clinically important effects independent of weight loss.

17 bic capacity, having >=5 illnesses, and >=5% weight loss.

18 tomach that is necessary to induce sustained weight loss.

19 e of rhesus macaques following FGF21-induced weight loss.

20 mposition following VSG prior to substantial weight loss.

21 ty liver disease (NAFLD) and is decreased by weight loss.

22 n in the lung and mitigated inflammation and weight loss.

23 Anhui/1/2013 by improving survival rates and weight loss.

24 n metabolic function that are independent of weight loss.

25 osis, is directly correlated with increasing weight loss.

26 concentrations and often resulting in modest weight loss.

27 progressive weakness in both lower limbs and weight loss.

28 ized that these changes would normalize with weight loss.

29 ion affected disease severity as measured by weight loss.

30 marked decrease after bariatric surgery and weight loss.

31 surgery is the most effective treatment for weight loss.

32 iral titers in the lung, lung pathology, and weight loss.

33 ed resistance, reduced aerobic capacity, and weight loss.

34 e of gut microbiota plasticity for sustained weight-loss.

35 P = 0.025], and lower odds of motivation for weight loss [0.81 (0.66, 0.99); P = 0.044] compared with

36 caused a reduction in EI (~400 kcal.d-1) and weight loss (-1.04 +/- 0.25 kg; P = 0.01) that was match

37 Successful weight loss (-11+/-5% body weight) was associated with i

38 ia (48 [15%]), low serum albumin (33 [10%]), weight loss (29 [9%]), and anaemia (28 [9%]), occurring

39 Mean adjusted excess weight loss 3 years after SG amounted to 62.3% (95% CI,

40 Metabolic adaptation was found after weight loss (-54 +/- 105 kcal/d; P < 0.001), with no dif

41 ealthy low-fat diet) and others tracked with weight loss (7 taxonomic changes in both diets).

42 gible participants (mean age, 52 years; mean weight loss, 8.3 kg) provided a fecal sample that was pr

43 bohydrate and low-fat diets can both lead to weight-loss, a substantial variability in achieved long-

44 satiety hormones, obesogenic behaviors, and weight loss, adjusted for age, sex, clinic site, year of

45 for benefit appeared to be approximately 5% weight loss after metabolic surgery and 20% in the nonsu

46 Interestingly, weight loss after obesity alters the AT immune compartme

47 en hospitals, there was a great variation in weight loss after SG.

48 While the weight-loss after RYGB was similar between hospitals, th

49 nate fat-free mass (FFM) loss (%FFML) during weight loss and 1) weight outcomes at 26 wk and 2) chang

50 airway mediator of the relationship between weight loss and AHI improvement.Conclusions: Weight loss

51 Weight loss and alleviation of insulin resistance were c

52 Weight loss and anorexia are common symptoms in cancer p

53 4 wk of weight stability at baseline, after weight loss and at 1 and 2 y.

54 tation at the level of RMR was present after weight loss and at 1- and 2-y follow-up, with measuremen

55 Weekly weight loss and barriers were evaluated during the ~19-w

56 Weight loss and cachexia were significantly (both p < 0.

57 Associations between weight loss and changes in these structures, and relatio

58 he neurobiological link between pathological weight loss and cognitive flexibility.

59 the airway was shown to effectively prevent weight loss and death in mice challenged with ten 50% le

60 Similarly, administration in hamsters limits weight loss and decreases lung titers and evidence of pn

61 When adjusted for percentage total weight loss and demographic variables, insulin cessation

62 Effective treatments include weight loss and exercise, positive airway pressure, oral

63 be treated with behavioral measures, such as weight loss and exercise.

64 ristics, YAC84Q mice showed a rescue of body weight loss and extended survival upon calpain-1 knockou

65 rocedures were safe, with RYGB having higher weight loss and follow-up rates at the cost of a slightl

66 s do not support the routine use of DJBL for weight loss and glucose control in patients with MS.

67 However, weight loss and glucose tolerance were improved in respo

68 istrated in the regain phase, might preserve weight loss and glycemic control, and is associated with

69 he bypass procedure may lead to more durable weight loss and glycemic control.

70 ce differences in metabolic adaptation after weight loss and if this phenomenon was associated with w

71 olonizes the lung accompanied by significant weight loss and immune cell infiltration and the express

72 ary injury that was also reflected from less weight loss and improved locomotive recovery of treated

73 Infected mice show both reduced weight loss and lower bacterial burden in circulating bl

74 Interindividual variability in weight loss and metabolic responses depends upon interac

75 n addition to malabsorption symptoms such as weight loss and micronutrient deficiency.

76 ibility to ZIKV clinical infection including weight loss and mortality each persists and is neither s

77 replication in tissues, extensive pneumonia, weight loss and mortality in a subset of animals.

78 ifelong and has been associated with chronic weight loss and muscle atrophy in mice.

79 both of these antibodies protected mice from weight loss and reduced the viral burden and levels of i

80 intensive lifestyle modification to promote weight loss and referral for bariatric surgery as indica

81 Repeated cycles of weight loss and regain, known as weight cycling, is ofte

82 ts of eTRF are independent of its effects on weight loss and represent chronic adaptations rather tha

83 e changes in gut microbiota, in facilitating weight loss and resolving associated comorbidities.

84 study further exemplifies the importance of weight loss and risk factor modification in AF managemen

85 ound that STING-deficient mice had increased weight loss and roughly 10-fold-increased systemic bacte

86 Weight loss and smoking cessation are often useful.

87 ibution of free-living PA to surgery-induced weight loss and subsequent weight regain is not well und

88 t surgery results in greater improvements in weight loss and type 2 diabetes outcomes, compared with

89 act, and disease signs and endpoints include weight loss and viral RNA and/or infectious virus in swa

90 e food intake was the strongest correlate to weight loss and was logarithmically related to gastric v

91 Furthermore, recent models of weight loss and weight cycling reveal additional roles f

92 k between these physiological adaptations to weight loss and weight regain is lacking.

93 on rotarod or grip strength but exacerbated weight loss and worsened performance on the pole test.

94 liminary data suggest that TRE produces mild weight loss, and also may improve some aspects of cardio

95 n-deficient mice showed increased morbidity, weight loss, and colon injury, with a concomitant increa

96 PGDHi attenuated both acute inflammation and weight loss, and decreased mortality.

97 ofiles with regard to food intake reduction, weight loss, and glucose control in preclinical animal m

98 focus on obesity, bariatric surgery-induced weight loss, and immune checkpoint blockade in cancer.

99 g intestinal tissue from damage, LPS-induced weight loss, and leukocyte infiltration.

100 ls: hearing impairment, mobility impairment, weight loss, and lower patient-reported health status.

101 rotected hamsters from SARS-CoV-2 infection, weight loss, and lung pathology.

102 analysis examined adherence, dietary intake, weight loss, and metabolic outcomes in overweight adults

103 broblast growth factor 21 (FGF-21) predicted weight loss, and none helped individualize dietary assig

104 acute abdominal pain, generalized weakness, weight loss, and pyrexia.

105 experienced decreased survival, had greater weight loss, and showed increased bacterial burden in th

106 nergy balance during development of obesity, weight loss, and subsequent weight regain.

107 tigue, abdominal pain, lower abdominal pain, weight loss, and the "any other symptom" category), more

108 d the reduced energy expenditure that follow weight loss are the main drivers of relapse.

109 his article in which we describe the typical weight loss, as well as the associated impact on both tr

110 ht-loss phase, and to prompt preservation of weight-loss-associated specific bacteria and microbial m

111 sex, preoperative body mass index (BMI) and weight loss at 1 year after surgery.

112 on at W13, and regained 29% of their initial weight loss at 1Y.

113 The percent weight loss at 24 months was significantly greater in th

114 opulation resulted in clinically significant weight loss at 24 months.

115 The percent of total weight loss at 30 and 90-days was not significantly diff

116 Also, to identify obesogenic behaviors and weight loss barriers associated with late eating.

117 467) g/wk; P = 0.008], higher odds of having weight-loss barriers [OR (95% CI): 1.22 (1.03, 1.46); P

118 rning symptoms of malignancy (eg, dysphagia, weight loss, bleeding) and those with other main risk fa

119 ropose that the physiological adaptations to weight loss, both at the level of the homeostatic appeti

120 Online programs may help with weight loss but have not been widely implemented in rout

121 These effects lead to increased weight loss, but do not require p75NTR during developmen

122 ymptoms due to low frequency of diarrhea and weight loss, but they were not statistically significant

123 .2 kg, whereas diet adherence increased mean weight loss by 1.1, 1.8, and 0.3 kg, respectively.

124 Weight loss by ketogenic diet (KD) has gained popularity

125 gastric artery, has been reported to promote weight loss by reducing ghrelin, an appetite-stimulating

126 In mice, FGF21 is thought to cause weight loss by stimulating thermogenesis, but whether FG

127 elevation in the NLR associates with greater weight loss, cachexia, and lower serum 25-hydroxyvitamin

128 lifestyle interventions such as exercise and weight loss can slow OA progression, but at later stages

129 w different monitoring strategies influenced weight loss (control, daily self-weighing, hunger traini

130 Weight loss decreased IHTG content, at least in part, by

131 Weight loss decreased IHTG content, in conjunction with

132 ein biomarkers and BMI at baseline, during a weight loss diet intervention, and to assess predictive

133 ght gain during overfeeding and resistant to weight loss during caloric restriction.

134 ow-calorie diet (LCD) resulting in >=8% body weight loss, during which changes in body composition (b

135 microbiota composition was not predictive of weight loss, each diet resulted in substantial changes i

136 ers had an average 80 g lower weekly rate of weight loss [early, 585 (667) g/wk; late, 505 (467) g/wk

137 A, including exercise and physical activity, weight-loss, education and support for self-management.

138 ulin sensitivity, no convincing evidence for weight-loss effects of cold-activated human BAT exists t

139 ); females 73.2% vs. 90.8% (p=0.005); excess weight loss (EWL) 53.8 +/- 28.1% vs. 57.4 +/- 25.5% (p=0

140 eria: slow walking speed, low grip strength, weight loss, exhaustion, and low physical activity.

141 presented to a rural facility complaining of weight-loss, fatigue, hematuria, dysuria, painful right

142 5% CI: 1.37, 2.88; n = 30; P < 0.001) higher weight loss for the NND group than the ADD group.

143 To date, clinical guidelines recommend a weight loss goal of 7%-10% to improve features of nonalc

144 terranean diet, and green-Mediterranean diet weight-loss groups.

145 the training set of 61 patients, excess body weight loss >95% (odds ratio [OR] 6.73, 95% confidence i

146 Weight loss >= 5%, tobacco use at LEMS onset and age at

147 capacity, having >=5 chronic illnesses, and weight loss >=5%.

148 aerobic capacity, having >=5 illnesses, and weight loss >=5%.

149 Weight loss has been identified as a negative prognostic

150 Additionally, whereas weight loss improved systemic insulin sensitivity in the

151 Weight loss improves OSA, but the mechanism is unknown.O

152 ver pattern was reported in 52% of patients, weight loss in 57%, and night sweats in 48%.

153 hibition of the mPFC-AcbSh pathway prevented weight loss in ABA and improved flexibility during early

154 Parallel attenuation of weight loss in ABA and improvement of cognitive flexibil

155 of food timing on cardiometabolic health and weight loss in adults.

156 Tumor energy requests can lead to extreme weight loss in animals and cachexia in cancer patients.

157 s that do not affect weight in humans caused weight loss in animals.

158 identify individual predisposing features of weight loss in combination with diet.

159 ) prevents weight gain and leads to dramatic weight loss in combination with glucagon-like peptide-1

160 g (IF) and Paleolithic (Paleo) diets produce weight loss in controlled trials, but minimal evidence e

161 letal muscle, to concordantly associate with weight loss in discovery and replication samples reachin

162 Level B weaker evidence (obesity in midlife, weight loss in late life, physical exercise, smoking, sl

163 and leptin dose do not predict the observed weight loss in lean individuals suggesting a saturable e

164 ese mice, but did not affect CL-induced body weight loss in male or female obese mice.

165 sitive hepatocytes in the liver, and rescued weight loss in mice.

166 Fibroblast growth factor 21 (FGF21) induces weight loss in mouse, monkey, and human studies.

167 orbid obesity and diabetes and diminish with weight loss in nondiabetic but not diabetic subjects, po

168 LB agonist antibody BFKB8488A induced marked weight loss in obese cynomolgus monkeys while elevating

169 ed by the 4 primary modalities for obtaining weight loss in obesity-dietary modification, increasing

170 in biomarkers might be useful for predicting weight loss in overweight and obese individuals.

171 Weight loss in response to energy restriction is highly

172 s before surgery was associated with greater weight loss in RYGB, but not VSG.

173 storage and metabolism due to FGF21-induced weight loss in the non-human primate model, and do not f

174 od as cisplatin but with the advantage of no weight loss in the subjects.

175 The most predictive models for weight loss included features of diet, gut bacterial spe

176 cal HRQoL throughout 7 years, independent of weight loss, indicating PA is a modifiable behavior to a

177 before and after matched (approximately 18%) weight loss induced by gastric bypass (surgery group) or

178 n with anorexia, dysphagia and unintentional weight loss initially diagnosed as achalasia.

179 nesis, while genetic or dietary induction of weight loss intercepts cancer development.

180 agnetic resonance imaging before and after a weight loss intervention (intensive lifestyle modificati

181 Obese volunteers were assigned to a dietary weight loss intervention, before reexamination.

182 bolic risk factors and reduced efficacy of a weight-loss intervention.

183 These findings confirm that weight loss is a heritable trait and provide evidence by

184 sed and sib-pair analysis, we show that that weight loss is a heritable trait, with estimated heritab

185 Weight loss is highly effective in preventing T2D; howev

186 duction may provide sufficient efficacy when weight loss is not the major goal of the surgical interv

187 In conclusion, if weight loss is the primary goal of surgical intervention

188 were similar and were apparently related to weight loss itself, with no evident clinically important

189 ledonia presenting with febrile splenomegaly,weight loss, life-threatening autoimmune haemolytic anem

190 articipants allocated either to an intensive weight-loss lifestyle intervention based on er-MedDiet,

191 trial (PREDIMED-Plus) based on an intensive weight-loss lifestyle intervention program.

192 Frailty encompasses 5 domains; weight loss, low physical activity, exhaustion, decrease

193 SS)-induced colitis, manifested by increased weight loss, macrophage infiltration, and inflammatory c

194 kg daily o.s.) was able to decrease the body weight loss, macroscopic damage, colon length, histologi

195 isorders, but the role of sleep in long-term weight loss maintenance (WLM) has not been thoroughly ex

196 Participants were randomly assigned into 5 weight loss maintenance diets based on protein and glyce

197 d by 4 wk of weight stabilization and a 9-mo weight loss maintenance program.

198 nce to the potential of these fatty acids in weight loss maintenance.

199 lass 3 obesity, for whom low weight gain and weight loss may be associated with decreased risk of SMM

200 diabetes remission after surgically-induced weight loss may be associated with reduced ability to pr

201 anges in body composition which occur during weight loss may have an influential role on subsequent e

202 Our results suggest that composition of weight loss may have functional importance for energy ba

203 most common surgical weight loss procedure, weight loss mechanisms remain less clear.

204 d when symptoms such as nausea and vomiting, weight loss, melena, hematemesis and deep anemia occur,

205 ester, symptoms such as nausea and vomiting, weight loss, melena, hematemesis and deep anemia should

206 After weight loss, metabolic adaptation at the level of RMR is

207 -oleoylethanolamide (OEA) were necessary for weight loss, metabolic improvements, and diet preference

208 ents and Main Results: Grp78 deletion caused weight loss, mortality, lung inflammation, and spatially

209 management (eg, advice on sleep positioning, weight loss; n = 51).

210 nonbanded sleeve gastrectomy (SG) regarding weight loss, obesity-related comorbidities, and complica

211 roducing small but statistically significant weight loss of 1-4%.

212 rt, polydipsia, polyuria, fatigue and recent weight loss of 10 kg.

213 so evaluated before and after a diet-induced weight loss of 10%.RESULTSThe contribution of hepatic DN

214 34.07 +/- 3.73 kg/m, representing total body weight loss of 25.13 +/- 4.44% and excess weight loss of

215 In post hoc analyses, weight loss of 5 kg or more within the 5-year period pre

216 dy weight loss of 25.13 +/- 4.44% and excess weight loss of 57.48 +/- 9.64% (P < 0.001).

217 lted in a higher rate of patients with total weight loss of more than 20% (95.8% vs 84.6%, P < 0.001)

218 ribe salivary microbiome changes during body weight loss on an individual-specific level, and to eluc

219 We also evaluated the effect of diet-induced weight loss on insulin secretion in people with obesity

220 known.Objectives: To determine the effect of weight loss on upper airway anatomy in subjects with obe

221 Bariatric surgery is the most effective weight loss option for Veterans with severe obesity, but

222 erative requirements were met: 7% total body weight loss or 6 months of counseling and no weight gain

223 ed up to 4 times) was well-tolerated without weight loss or organ hypertrophy.

224 nvestigations, unless alarm symptoms such as weight loss or rectal bleeding are present, or there is

225 r to those with concerning features, such as weight loss or vomiting.

226 eatment of diabetes, regardless of perceived weight loss outcomes.

227 diet make it difficult to foresee individual weight-loss outcomes.

228 He reported a 10-kg weight loss over 4 months but denied experiencing fever,

229 ssessments (n=3902), improvements in CRF and weight loss over a 4-year follow-up were significantly a

230 olerated and promotes clinically significant weight loss over a sham procedure.(The Lowering Weight i

231 Other adverse reactions, including weight loss, oxidative stress and angiogenesis, are repo

232 Also, they reduced weight loss, oxidative stress, and the anthracnose (Coll

233 001); results remained after controlling for weight loss (Pearson's rho = 0.36, P = 0.014).

234 A considerable reduction in colour indices, weight loss, pH and titratable acidity, reducing sugars,

235 Autologous FMT, collected during the weight-loss phase and administrated in the regain phase,

236 In mice, Mankai-modulated aFMT in the weight-loss phase compared with control diet aFMT, signi

237 After 6 months (weight-loss phase), 90 eligible participants (mean age,

238 change in microbiome composition during the weight-loss phase, and to prompt preservation of weight-

239 ses and protected against SARS-CoV-2-induced weight loss, pneumonia and mortality.

240 w allow for analysis of multiple factors for weight loss prediction at the individual level.

241 f low AMY1 CN and pretreatment P/B ratio for weight loss prediction led to highly individualized weig

242 Outcomes were differences in weight loss (primary outcome) and recruitment and retent

243 ne BMI was 29.5 kg/m2 (SD 5.1), and the mean weight loss prior to baseline assessments was 11.4 kg (S

244 astrectomy becoming the most common surgical weight loss procedure, weight loss mechanisms remain les

245 er concentrations of toxic elements during a weight loss program could pose a risk to human health.

246 aluate preliminary efficacy of Aussie-FIT, a weight-loss program for men with overweight/obesity deli

247 Participants were recruited from a weight-loss program in Spain.

248 .3 y; 88 whites and 83 blacks] enrolled in a weight-loss program to achieve a BMI <25, and were follo

249 tween cognitive flexibility and pathological weight loss provides a unique insight into the executive

250 weight loss and AHI improvement.Conclusions: Weight loss reduced volumes of several upper airway soft

251 ciated with no decrease in fibrosis and less weight loss (reduction in body mass index of 6.3 +/- 4.1

252 Here we study the mineral profile of weight loss related products, including the analysis of

253 achieve and maintain the necessary degree of weight loss required for therapeutic effect.

254 study was to determine the minimum amount of weight loss required to see a reduction in major adverse

255 ions improved rates of smoking cessation and weight loss, respectively.

256 Here, we classify weight loss responders (N = 106) and non-responders (N =

257 loss prediction led to highly individualized weight loss results with the introduction of more fiber,

258 Weight loss reverses these energetic changes.

259 Weight loss scores demonstrated nonstatistical improveme

260 Dietary and medical weight loss strategies are frequently unsuccessful and u

261 ns have NAFLD and ketogenic diets are common weight loss strategies.

262 re is a growing need for effective long-term weight-loss strategies, coupled with an understanding of

263 mittent fasting has grown in popularity as a weight loss strategy in recent years.

264 composition or diversity was associated with weight-loss success.

265 signals in overnutrition may be modulated by weight loss, such as that induced by bariatric surgery.

266 Furthermore, adenosine prevented weight loss, tachycardia, and compromised lung function

267 The primary endpoint was 6-month total body weight loss (TBWL).

268 pecific bacterial signatures associated with weight loss that were consistent across both cohorts.

269 e size of the residual stomach and sustained weight loss, this begs the question whether less aggress

270 matched-cohort study identified the minimum weight loss thresholds for reduction in risk of MACE and

271 t also ameliorates diabetes independently of weight loss through mechanisms that are not fully unders

272 e GVHD process was observed with progressive weight loss, tissue damage, and death censoring.

273 rbidity and mortality, the minimum amount of weight loss to have a meaningful impact on cardiovascula

274 ed Controlled Trial Polyphenols-Unprocessed) weight-loss trial (May 2017 through July 2018), abdomina

275 erse events included anaemia (four [6%]) and weight loss (two [3%]).

276 tivity was not accompanied by any noticeable weight loss (up to 20 weeks post end of dosing).

277 crobiota explain a portion of variability in weight-loss using two cohorts of obese adults enrolled i

278 Besides inducing significant weight loss, VSG also improves glucose tolerance.

279 At 12 mo, weight loss was -4.0 kg (95% CI: -5.1, -2.8 kg) in IF, -

280 Total weight loss was 27.8% and -0.1% in the RYGB and MT group

281 eight difference, and baseline weight), only weight loss was associated with a significant decrease i

282 Weight loss was associated with increases in mean suppre

283 A lipogenesis gene module associated with weight loss was evaluated by testing the function of mem

284 Improved AHI with weight loss was mediated by reductions in tongue fat.

285 bdominal pain was more common in adults, and weight loss was more common in the elderly.

286 Ongoing weight loss was reported by 10.4% of patients, and only

287 were examined.Measurements and Main Results: Weight loss was significantly associated with reductions

288 Inflammation, clinical score, and weight loss were also lower in M. muris-pretreated mice.

289 ne CRF and sustained improvements in CRF and weight loss were associated with lower risk of HF.

290 ML and change in appetite perceptions during weight loss were inconsistent.

291 No clinical signs or weight loss were observed.

292 ays), and 1-year results (follow-up rate and weight loss) were studied.

293 Although fat oxidation is essential for weight loss, whether it remains beneficial when sustaine

294 soluble fiber was associated with postpartum weight loss, which may partially offset the obesogenic e

295 , the WT and its I38T mutant induced similar weight loss with comparable lung titers in both viral su

296 ing wasting syndrome characterized by severe weight loss with specific losses of muscle and adipose t

297 bohydrate or lower-fat diets and concomitant weight loss with the composition and diversity of the gu

298 - to post-surgery changes, less post-surgery weight loss, worsening physical and mental health status

299 We hypothesized that weight loss would decrease soft tissue volumes and tongu

300 y bariatric procedure, SG leads to excellent weight loss, yet weight regain is a relevant issue in mi